Technical Analysis for ZYME - Zymeworks Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Oversold Stochastic | Weakness | 0.00% | |
Spinning Top | Other | -0.93% | |
Calm After Storm | Range Contraction | -0.93% | |
NR7 | Range Contraction | -0.93% | |
Oversold Stochastic | Weakness | -0.93% | |
Calm After Storm | Range Contraction | -0.56% | |
Outside Day | Range Expansion | -0.56% | |
Oversold Stochastic | Weakness | -0.56% | |
MACD Bearish Centerline Cross | Bearish | -0.37% | |
Calm After Storm | Range Contraction | -0.37% |
Alert | Time |
---|---|
60 Minute Opening Range Breakout | about 17 hours ago |
Down 3% | about 19 hours ago |
Lower Bollinger Band Support | about 19 hours ago |
Fell Below Previous Day's Low | about 19 hours ago |
Down 2 % | about 19 hours ago |
Get a Trading Sidekick!
- Earnings date: 08/02/2023
Zymeworks Inc. Description
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Immune System Cancer Immunotherapy Monoclonal Antibodies Antibody Toxins Glycoproteins Her2 Protein Engineering Biological Systems Bispecific Monoclonal Antibody
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 13.14 |
52 Week Low | 6.015 |
Average Volume | 403,721 |
200-Day Moving Average | 8.69 |
50-Day Moving Average | 11.23 |
20-Day Moving Average | 11.70 |
10-Day Moving Average | 11.20 |
Average True Range | 0.53 |
RSI (14) | 39.76 |
ADX | 28.89 |
+DI | 13.06 |
-DI | 23.62 |
Chandelier Exit (Long, 3 ATRs) | 11.55 |
Chandelier Exit (Short, 3 ATRs) | 12.04 |
Upper Bollinger Bands | 13.03 |
Lower Bollinger Band | 10.37 |
Percent B (%b) | 0.13 |
BandWidth | 22.81 |
MACD Line | -0.15 |
MACD Signal Line | 0.05 |
MACD Histogram | -0.2032 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 11.39 | ||||
Resistance 3 (R3) | 11.37 | 11.14 | 11.27 | ||
Resistance 2 (R2) | 11.14 | 10.96 | 11.14 | 11.23 | |
Resistance 1 (R1) | 10.92 | 10.86 | 10.81 | 10.94 | 11.20 |
Pivot Point | 10.69 | 10.69 | 10.63 | 10.69 | 10.69 |
Support 1 (S1) | 10.47 | 10.51 | 10.36 | 10.49 | 10.22 |
Support 2 (S2) | 10.24 | 10.41 | 10.24 | 10.19 | |
Support 3 (S3) | 10.02 | 10.24 | 10.15 | ||
Support 4 (S4) | 10.04 |